CryoPort Stock News

New High-Volume Shipping System, Improving Patient Accessibility, Will Be Showcased by Cryoport Systems at Phacilitate's Advanced Therapies Week in Dallas NASHVILLE, Tenn. , Jan. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today unveiled its Cryoport Express® Cryogenic HV3 Shipping System ...

Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn.

All Three MVE Biological Solutions' Manufacturing Facilities Are Registered With the FDA and All Applicable MVE Products Are Now Listed NASHVILLE, Tenn. , Jan. 6, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences industry, today announced that MVE Biological Solutions ("MVE"), a Cryoport company and the leading global manufacture...

Cryoport operates in the promising life sciences sector but continues to suffer from poor fundamentals and significant cash flow challenges. Despite slight revenue growth in Q3 2024, the company remains unprofitable and has seen a drastic share price decline since my initial 'sell' rating. Recent financial improvements are minimal, with net losses narrowing and cash flow turning slightly positi...

Facility Dedicated to Cryopreservation of Leukapheresis Starting Materials to Support Clinical and Commercial Cell-Based Therapy Programs NASHVILLE, Tenn. , Nov. 12, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced the opening of its newest IntegriCell™ facility in Villers-...

Cryoport, Inc. (NASDAQ:CYRX ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP Investor Relations and Corporate Development Conference Call Participants ...

Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year Supported a record total of 691 global clinical trials as of September 30, 2024 Company reaffirmed full year 2024 revenue guidance of $225 to $235 million NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply ch...

NASHVILLE, Tenn. , Oct. 29, 2024 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the third quarter ended September 30, 2024 on Thursday, November 7, 2024 after U.S. markets close.